ArticleMolecular cancer therapeutics2012
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanism.
Article in Molecular cancer therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 84 citations in OpenAlex.
- An optical coherence tomography study of a photoactive Pt(iv) prodrug in oesophageal tissue.RSC advances · 2025Article
- Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy.Inorganic chemistry · 2023Article
- Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.Journal of the American Chemical Society · 2021Article
- Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand.Molecules (Basel, Switzerland) · 2021Article
- The Role of Triplet States in the Photodissociation of a Platinum Azide Complex by a Density Matrix Renormalization Group Method.The journal of physical chemistry letters · 2021Article
- DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds.Frontiers in oncology · 2021Article
- Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action.Molecules (Basel, Switzerland) · 2020Review
- New Designs for Phototherapeutic Transition Metal Complexes.Angewandte Chemie (International ed. in English) · 2020Review
- Sequence-dependent attack on peptides by photoactivated platinum anticancer complexes.Chemical science · 2018Article
- Photoactivated inhibition of cathepsin K in a 3D tumor model.Biological chemistry · 2016Article
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.Chemical reviews · 2016Review
- Combination of Ru(ii) complexes and light: new frontiers in cancer therapy.Chemical science · 2015Article
- Photorelease of Pyridyl Esters in Organometallic Ru(II) Arene Complexes.Molecules (Basel, Switzerland) · 2015Article
- Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments.Science progress · 2014Review
- De novo generation of singlet oxygen and ammine ligands by photoactivation of a platinum anticancer complex.Angewandte Chemie (International ed. in English) · 2013Article
- Photoactivatable metal complexes: from theory to applications in biotechnology and medicine.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2013Review
- Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.Chemistry (Weinheim an der Bergstrasse, Germany) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that trans,trans,trans-[Pt(IV)(N(3))(2)(OH)(2)(py)(NH(3))] complex 3 is a potent photoactivated cytotoxin toward human cancer cells in culture, with an average IC(50) value in 13 cell lines of 55 ± 28 μmol/L after 30 minutes (0.12 mW/cm(2)) photoactivation with UVA, although visible light was also effective. Photoactivated complex 3 was noncross-resistant to cisplatin in 3 of 4 resistant cell lines. Cell swelling but very little blebbing was seen for HL60 cells treated with irradiated complex 3. Unlike cisplatin and etoposide, both of which cause apoptosis in HL60 cells, no apoptosis was observed for UVA-activated complex 3 by the Annexin V/propidium iodide flow cytotometry assay. Changes in the levels of the autophagic proteins LC3B-II and p62 in HL60 cells treated with UVA-activated complex 3 indicate autophagy is active during cell death. In a clonogenic assay with the SISO human cervix cancer cell line, 3 inhibited colony formation when activated by UVA irradiation. Antitumor activity of complex 3 in mice bearing xenografted OE19 esophageal carcinoma tumors was photoaugmented by visible light. Insights into the novel reaction pathways of complex 3 have been obtained from (14)N{(1)H} nuclear magnetic resonance studies, which show that photoactivation pathways can involve release of free azide in buffered solution. Density functional theory (DFT) and time-dependent DFT calculations revealed the dissociative character of singlet and triplet excited states of complex 3, which gives rise to reactive, possibly cytotoxic azidyl radicals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.